Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SP 1049C

Drug Profile

SP 1049C

Alternative Names: Doxorubicin SP1000 - Supratek Pharma; SP-1049C

Latest Information Update: 19 Jan 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Supratek Pharma
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Oesophageal cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Adenocarcinoma

Most Recent Events

  • 19 Jul 2013 Biomarkers information updated
  • 19 Jan 2011 No development reported - Phase-II for Adenocarcinoma in United Kingdom (IV)
  • 28 Nov 2007 US FDA, under a Special Protocol Assessment (SPA), approves the design of phase III study protocol of SP 1049C in metastatic adenocarcinoma of the upper GI
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top